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ABSTRACT
Introduction: A vast increase in knowledge of
numerous aspects of malignant salivary gland
tumours has emerged during the last decade
and, for several reasons, this has not been the
case in benign epithelial salivary gland
tumours. We have performed a literature review
to investigate whether an accurate histological
diagnosis of the 11 different types of benign
epithelial salivary gland tumours is correlated to
any differences in their clinical behaviour.
Methods: A search was performed for histolog-
ical classifications, recurrence rates and risks for
malignant transformation, treatment modali-
ties, and prognosis of these tumours. The search
was performed primarily through PubMed,
Google Scholar, and all versions of WHO clas-
sifications since 1972, as well as numerous
textbooks on salivary gland tumours/head and
neck/pathology/oncology. A large number of
archival salivary tumours were also reviewed
histologically.
Results: Pleomorphic adenomas carry a con-
siderable risk (5–15%) for malignant
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transformation but, albeit to a much lesser
degree, so do basal cell adenomas and Warthin
tumours, while the other eight types virtually
never develop into malignancy. Pleomorphic
adenoma has a rather high risk for recurrence
while recurrence occurs only occasionally in
sialadenoma papilliferum, oncocytoma,
canalicular adenoma, myoepithelioma and the
membranous type of basal cell adenoma.
Papillomas, lymphadenoma, sebaceous ade-
noma, cystadenoma, basal cell adenoma (solid,
trabecular and tubular subtypes) very rarely, if
ever, recur.
Conclusions: A correct histopathological diag-
nosis of these tumours is necessary due to (1)
preventing confusion with malignant salivary
gland tumours; (2) only one (pleomorphic
adenoma) has a considerable risk for malignant
transformation, but all four histological types
of basal cell adenoma can occasionally develop
into malignancy, as does Warthin tumour; (3)
sialadenoma papilliferum, oncocytoma,
canalicular adenoma, myoepithelioma and
Warthin tumour only occasionally recur; while
(4) intraductal and inverted papilloma, lym-
phadenoma, sebaceous adenoma, cystadenoma,
basal cell adenoma (apart from the membra-
nous type) virtually never recur. No biomarker
was found to be relevant for predicting recur-
rence or potential malignant development.
Guidelines for appropriate treatment strategies
are given.
Keywords: Benign salivary gland tumours;
Biomarkers; Malignant transformation;
PubMed; Recurrence; Salivary gland
neoplasms; Treatment modalities
INTRODUCTION
An impressive increase in knowledge of the
genetics, pathogenesis, diagnostic possibilities,
clinical behavior, treatment modalities and
prognosis of malignant salivary tumours has
emerged during the last decade. A similar
development has not happened with regards to
benign salivary neoplasms, in despite the fact
that a few of these are precursors to the malig-
nant variants. The current 4th World Health
Organization (WHO) classification of 2017
defines 11 different types of benign epithelial
salivary tumours (some of them with subclassi-
fications), 4 non-neoplastic epithelial lesions (1
of which future studies possibly may give evi-
dence that it may be a neoplasm–sclerosing
polycystic adenosis), 3 benign soft tissue
lesions/tumours, and 22 carcinomas [1]. This is
to be compared to the 1st WHO edition of 1972
that comprised just two adenomas (pleomor-
phic and monomorphic adenoma), two
tumours (acinic cell tumour ad mucoepider-
moid tumour) and five carcinomas [adenoid
cystic carcinoma, adenocarcinoma, epidermoid
carcinoma, undifferentiated carcinoma and
carcinoma in pleomorphic adenoma (PA)] [2]. A
modified classification was proposed by Seifert
et al. in 1990 [3] that led to the publication of
the 2nd WHO classification in 1991 by which
time the two recognisable benign tumour enti-
ties had risen to nine (two of which had sub-
classifications) [4]. With the continuous
increase of knowledge, and a wider use of
immunohistochemistry and molecular tech-
niques, the separate entities have been better
characterized and more widely accepted. Sali-
vary gland tumours were included in the 3rd
and 4th editions of WHO classifications of head
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and neck tumours (2005 and 2017, respectively)
instead of being published in separate books
[1, 5]. The histological identification of PA,
Warthin tumour (WT) and, to a certain extent
myoepithelioma (MYO), is usually relatively
straightforward, but the classification of some
of the other eight benign tumours can on
occasion be rather difficult, primarily due to
their rareness in a routine pathology laboratory
set-up. Many may perhaps agree with Zarbo
et al. in their statement related to less common
benign salivary gland tumours ‘‘To wit, we
believe it does not matter what these tumours
are called as long as they are recognized and
designated benign and the adequacy of excision
is noted’’ [6]. However, it appears that some of
the benign salivary gland tumours do have a
tendency to recur, others have a very low ten-
dency, while yet some others do not recur at all.
A few are known to develop into malignant
neoplasms, while in others malignant transfor-
mation is extremely rare, or has not yet even
been reported. Therefore, the aims of this study
were to investigate via a search in the medical
literature, whether the study of any biomarker
and a correct histological subclassification
would detect the risk for recurrence and/or
potential malignant transformation for the dif-
ferent benign tumours. If so, the individual
patient should more often benefit from receiv-
ing the most appropriate treatment as well as be
given a correct evidence-based prognosis.
METHODS
A thorough medical literature search has been
performed, primarily PubMed, Google Scholar,
numerous text books on head and neck
pathology/salivary gland pathology/surgery/
oncology, and the different editions of WHO
classifications of salivary gland tumours. Each
benign entity as defined by the 2017 WHO
classification is listed in Table 1.
We describe here the histological character-
istics of the 11 different types of benign
epithelial salivary tumours and, for each entity,
have studied the recurrence and malignant
transformation potential, and the presence of
any predictive factor.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors. The studies involved fully
complied with the ethical standard of the hos-
pitals involved and in accordance with the
Helsinki Declaration of 1964 and its later
amendments. No informed consent from
patients was required due to this being a retro-
spective study of archival histological material
with de-identified data.
RESULTS
The incidence and anatomical site of the
tumours are outlined in Tables 2 [7–15] and 3
[7–10, 14, 15]. The data have been collected
from a few large series from different parts of
the world which show wide variations between
them. Totals of 2280 cases are reported in
Table 2 and 1847 in Table 3. The latter compi-
lation contains some cases also present in
Table 2, but where the exact anatomical loca-
tion was not given, hence a total of 2280 benign
salivary gland tumours. These studies primarily
comprise intraoral tumours, and the compiled
data will only serve as a rough guideline.
Intraoral tumours indicate oral tumours but
also in some series include major salivary gland
Table 1 2017 WHO classiﬁcation of benign epithelial
salivary gland tumours (from El-Naggar et al. [1])
Pleomorphic adenoma myoepithelioma
Basal cell adenoma (membranous, solid, trabecular and
tubular types; often mixtures thereof) Warthin
tumour
Oncocytoma
Lymphadenoma (sebaceous and non-sebaceous
lymphadenoma) cystadenoma
Sialadenoma papilliferum
Ductal papilloma (intraductal and inverted ductal
papilloma) Sebaceous adenoma
Canalicular adenoma
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tumours affecting the oral cavity (sub-
mandibular, parotid and sublingual). However,
benign tumours in, e.g., trachea, larynx, etc. are
not included. For example, approximately 80%
of basal cell adenomas (BCAs) occur in major
salivary glands and in studies comprising only
intraoral tumours the true relative frequency of
BCAs in comparison with other adenomas will
of course not be correctly reflected. These
studies clearly indicate that adenomas, other
than PA, WT, canalicular adenoma, and BCAs,
are all quite rare. An accurate estimate of the
Table 3 Anatomical location of 1847 intraoral benign epithelial salivary gland tumours from six international series (Refs.
[7–10, 14, 15])
Type Palate Lip Buccal mucosa FOM Retromolar region Tongue Total
Upper Lower
BCA 6 6 – 2 – – 1 15
CA 7 37 – 4 – – 1 49
CYA 16 2 1 1 13 1 – 7 41
DP 10 1 4 6 3 – 3 27
PA 1140 89 73 9 155 2 7 5 1480
WT 3 – – 1 – – 1 5
MYO 208 3 2 – 11 1 – 4 229
SA – – – 1 – – – 1
FOM ﬂoor of the mouth, BCA basal cell adenoma, CA canalicular adenoma, CYA cystadenoma, DP ductal papilloma, PA
pleomorphic adenoma, WT Warthin tumour, MYO myoepithelioma, SA sebaceous adenoma
Table 2 2280 benign epithelial intraoral minor salivary gland tumours
Yih
et al.
[7]
Buchner
et al. [8]
Wang
et al.
[10]
Jones
et al.
[9]
Tian
et al.
[11]
Luksˇic´
et al.
[12]
Bradley and
McGurk [13]
Wang
et al.
[14]
Shen
et al.
[15]
No of benign tumours 119 224 333 481 734 80 59 268 282
Basal cell adenoma – 2.7 1.2 7.7 0.7 – 3.4 2.6 0.7
Oncocytoma 0.9 – – 1.0 1.2 – – – –
Canalicular adenoma 21.0 10.2 – 7.3 0.1 – 10.2 – –
Sebaceous adenoma – – – 0.2 – 1.3 – – –
Cystadenoma – 10.7 1.8 3.1 1.2 1.3 1.7 1.1 0.4
Ductal papilloma – 7.5 0.6 2.2 1.2 – – 1.9
Pleomorphic adenoma 78.1 66.7 81.7 68.5 89.6 97.5 78.0 67.2 93.6
Warthin tumour – – 0.3 7.1 – – – 0.7 0.7
Myoepithelioma – 2.2 14.4 2.9 7.1 – 6.8 26.5 4.3
The ﬁgures are given as percentages of benign tumours in each series. A proportion of cases in some of the studies above
included major salivary gland tumours as well as malignant tumours; none of the malignant tumours have been included in
this table. Non-intraoral tumours were also excluded
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incidence of each tumour entity is extremely
difficult to obtain as geographical and racial
differences exist, as well as changes in nomen-
clature over the years. Further, several of the
larger studies only comprise intraoral or only
major salivary gland tumours, while some
include both major and minor salivary gland
tumours. The criteria to differentiate between
PA and myoepithelioma (i.e., presence of ducts,
few ducts or no ducts) may differ between
pathologists. Hence, an absolute correct com-
pilation and estimation of incidences is not
possible and has to be considered when reading
the data given in Tables 2 and 3. For example, in
a non-Asian population, canalicular adenoma is
the most common adenoma of the 7 ‘‘rare’’
benign tumours, with an incidence similar to
myoepithelioma, some 5–12%, of all benign
tumours [7–9]. Reports from China are in sharp
contrast, and the study by Wang and associates
did not report a single case of canalicular ade-
noma amongst 737 cases of intraoral minor
salivary gland tumours [10].
One very good effort at establishing the true
incidence of benign salivary gland tumours was
carried out by Bradley and McGurk, examining
the unified computerised pathology records of
two teaching hospitals covering a fixed popu-
lation in the United Kingdom over two 10-year
periods [13].
In the 2005 WHO classification, sialolipoma
and keratocystoma were mentioned, but not as
separate entities, and, due to lack of further
substantial evidence since 2005, keratocystoma
has been omitted entirely from the 2017 edi-
tion. Sialolipoma, however, is included as a
separate entity, but as a soft tissue tumour
rather than an epithelial tumour.
Lymphadenoma
Lymphadenoma (LA) is a rare tumour with no
sex predilection and mostly affecting adults
aged[30 years. The first report is attributed to
McGavran and associates in 1960 [16]. Lui et al.
reported 10 new cases in 2014, and at that time
fewer than 110 cases had been reported in the
English literature [17]. Thereafter, only a few
case reports are available. LA is histologically
characterised as being a circumscribed, often
encapsulated, tumour consisting of benign
basal and squamous cells, and can possibly be
regarded as a BCA or cystadenoma accompanied
by dense lymphoid tissue. The solid epithelial
islands and trabeculae are basaloid cells while
the cysts or gland-lining cells are ductal. The
lymphoid component can be with or without
lymphoid follicles. There are histologically two
types of LA, the non-sebaceous adenoma with
epithelial cell nests accompanied by often a
prominent lymphoid stroma (Fig. 1a), and a
sebaceous variant. In the sebaceous type, the
peripheral (basaloid) epithelial cells are arran-
ged in nests with partial sebaceous differentia-
tion. The sebaceous type is more common and
accounts for approximately two-thirds of LA
cases. The parotid gland is the most common
site for all lymphadenomas ([ 80%).
Lymphadenomas are cured by complete
excision, and recurrence does not seem to
occur. Malignancy arising in sebaceous LA has
been reported on exceedingly few occasions. In
2003, Croitoru and associates reported one case
of LA with transition to a sebaceous carcinoma,
and they state that only three cases had been
reported [18]. However, with regards to the two
previously reported cases, the authors con-
cluded that the two cases of sebaceous lym-
phadenocarcinoma had arisen from sebaceous
glandular remnants in a lymph node and thus
not necessarily from a pre-existing LA [19]. On
the other hand, the study by Seethala et al. of 33
cases of LAs convincingly demonstrated one
case of malignant transformation of a LA to a
sebaceous carcinoma (and one case to a basal
cell adenocarcinoma) [20]. Hence, the extreme
rarity, and possibly also confusion between
lymphadenocarcinoma and sebaceous carci-
noma, is further emphasised by the fact that
neither lymphadenocarcinoma nor sebaceous
lymphadenocarcinoma are listed in the 2017
WHO classification as separate entities, in con-
trast to sebaceous adenocarcinoma [21]. Albeit a
totally benign tumour, LA can be misdiagnosed
as metastatic adenocarcinoma in a parotid
lymph node or possibly even as a lymphoep-
ithelial carcinoma. LA is virtually always well
circumscribed, which distinguishes it from
lymphoepithelial sialadenitis. A recent finding
1954 Adv Ther (2019) 36:1950–1974
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indicating an increased proportion of IgG4-
positive plasma cells in LA may suggest that the
pathogenesis involves an immune reaction
similar to what may be the case with WT [22].
Sebaceous Adenoma
Sebaceous glands are common in the parotid
gland (10–42% of glands), less frequently so in
the submandibular glands (5–6% of glands),
and very common in the oral mucosa which are
found in up to 80% of individuals (Fordyce’s
spots) [19, 23–25]. According to Gnepp, salivary
gland sebaceous neoplasms can be classified
into five groups: sebaceous adenoma (SA), and
sebaceous lymphadenoma, sebaceous carci-
noma, sebaceous lymphadenocarcinoma, and
sebaceous differentiation in other tumours [24].
Primary salivary gland sebaceoma has to our
knowledge not been reported. The authors of
the present study are not in full agreement in
recognising sebaceous lymphadenocarcinoma
as an existing entity, a view apparently shared
by the majority of the authors and editors of the
2017 WHO classification, as sebaceous lym-
phadenocarcinoma is not listed as a separate
tumour entity [1, 26].
SA is a very rare tumour, estimated to
account for some 0.1% of salivary neoplasms
and less than 0.5% of all salivary gland adeno-
mas; in 2012, only about 30 cases had been
reported [24]. Most cases (60%) arise in the
major salivary glands with 5 out of 6 in the
parotid gland. The buccal mucosa is the most
common site when located in minor salivary
glands [26]. SA is readily recognised as being a
well-circumscribed to -encapsulated mass com-
posed of solid nests of sebaceous cells embedded
in a fibrous stroma (Fig. 1b). Squamous and
oncocytic metaplasia, as well as foreign body
giant cells, may be present. The sebaceous cells
are immunoreactive for, e.g., epithelial mem-
brane antigen (EMA), p63 and androgen recep-
tors but also for more unusual antibodies like
adipophilin and perilipin (rarely available in
non-specialised laboratories). Sebaceoma that
occurs in the skin can be a differential diagno-
sis, but no convincing case of salivary seba-
ceoma has to our knowledge been reported.
Sebaceous adenoma is not known to recur
after adequate surgery [26]. Sebaceous carci-
noma is recognised in the 2017 WHO classifi-
cation and some 50 cases have been reported,
for example as the malignant component in
carcinoma ex pleomorphic adenoma (CXPA).
Most, if not all, of the few cases reported appear
to have arisen de novo and not from a pre-ex-
isting sebaceous adenoma [25, 27]. A recent
study of ten new cases of sebaceous adenocar-
cinoma also supports that they arise de novo as
none of the ten reported cases had arisen from a
pre-existing sebaceous adenoma [28].
Oncocytoma
Oncocytoma (OC) is to be distinguished from
diffuse and nodular oncocytosis and in the
parotid possibly also from WT (Fig. 1c, d). A
parotid fine needle aspirate, or core biopsy,
comprising only of small groups of oncocytic
cells can easily be appreciated as a WT but may
well represent parotid oncocytosis [29]. Onco-
cytoma represents approximately 2% of all
salivary gland neoplasms, occurs in elderly
patients, and most cases are located in the par-
otid gland, though also in the submandibular
gland and minor salivary glands [30, 31].
Oncocytoma is a well-circumscribed tumour
and consists of large epithelial oncocytic cells
with abundant eosinophilic granular cytoplasm
bFig. 1 a Lymphadenoma, non-sebaceous type. In a few of
the epithelial cell nests, a central ductal structure is present.
b Sebaceous adenoma with solid nests of sebaceous cells (a,
b adapted from Hellquist and Skalova [25]). c Well-
encapsulated (arrow) oncocytoma consisting of rather large
oncocytes. d Parotid nodular oncocytosis. Note the
absence of capsules. e Cystadenoma where the cysts are
separated by thin ﬁbrous septa. There are smaller papillary
intraluminal projections and the cysts are often ﬁlled with
eosinophilic ‘‘proteinaceous debris’’. f Palatal sialadenoma
papilliferum with an exophytic mildly papillary surface
epithelium and underlying cystic proliferation of salivary
ducts. g Higher magniﬁcation of the ductal proliferation;
note more columnar and taller cells and also thicker
ﬁbrous septa than in cystadenoma (e). h CK7 stain
highlights the salivary ductal cells with some ducts opening
up in the exophytic CK7 negative surface epithelium
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resulting from an accumulation of mitochon-
dria, possibly due to mutations in mitochon-
drial DNA, as is the case in OC of other
anatomical locations [32]. The cells thus stain
with phosphotungsten acid haematoxylin and
are strongly positive for CK7 and low-molecular
weight cytokeratins. OCs are also strongly, but
more patchily, positive for CK14, high-molec-
ular weight cytokeratins and EMA. Oncocytes in
OC are negative for CD10, in contrast to onco-
cytic renal cell carcinoma cells.
The basal cell population present in OC are
positive for, e.g., p63 and CK5/6, which can be
of help in distinguishing oncocytoma from
acinic cell carcinoma [33]. The p63 positivity
clearly discriminates oncocytic parotid cells
from being metaplastic renal cell carcinoma
cells. Hence, positive p63 and negative CD10
are together two strong biomarkers for oncocy-
toma, differentiating it from metastatic renal
cell carcinoma, but are not predictive markers
for recurrence or malignant transformation of
oncocytoma.
Further, in contrast to acinic cell carcinoma
with oncocytic cells, OC is negative for SOX10
and DOG1 [34]. DOG1 is an acinar and inter-
calated duct marker in salivary gland tissue and
therefore not surprisingly negative in OCs [35].
A novel possibly promising immunohisto-
chemical marker for oncocytic cells is the so-
called BSND marker. The Barkitt gene (associ-
ated with, e.g., sudden deafness) encodes
essential beta subunit for CLC chlorine chan-
nels, a protein involved in chloride transport,
and is expressed in normal kidney and the inner
ear, and also known as an immunohistochemi-
cal marker for chromophobe renal cell carci-
noma and renal oncocytoma. BSND has
recently been found to be expressed in the
striated duct cells of normal salivary glands and
has 100% positivity in WT and OC, while total
negativity was demonstrated in 11 PAs, 7 ade-
noid cystic carcinomas, 6 acinic cell carcino-
mas, 6 mucoepidermoid carcinomas and 5
salivary duct carcinomas [36]. The BSND anti-
body does not discriminate between oncocytic
renal tumour cells, WT or OC, but positivity
excludes other salivary tumours with oncocytic
cell participation, for example mucoepidermoid
carcinoma and PA. The oncocytes are arranged
as nests and sheets, trabeculae or ductal struc-
tures, and may contain cysts. The cells are often
separated by a thin fibrovascular stroma. On
very rare occasions, the major or entire part of
the tumour may consist of clear cells (clear cell
oncocytoma) [37], and in these cases several
other differential diagnoses will become
relevant.
Oncocytomas generally do not recur; how-
ever, they may be multifocal and any additional
parotid OC not excised on the first occasion
may incorrectly be appreciated as a recurrence.
Oncocytic carcinoma does exist (see below), but
the literature does not provide any substantial
evidence that these exceedingly rare cases have
arisen from a pre-existing OC [31, 38].
Cystadenoma
This tumour is not that rare in comparison with
other salivary tumours, comprising at least 4%
of benign salivary gland tumours [39, 40], and is
primarily characterised by a multicystic nature.
It is typically lined with proliferative, often
papillary, and not infrequently oncocytic
epithelium. The multicystic appearance is in
contrast to unicystic tumours like, e.g., intra-
ductal papilloma. Albeit both the 2005 and
2017 WHO editions mention cystadenoma to
be unilocular in quite a high percentage of
cases, these statements, however, refer to one
study of a case report of two cases [41] and
another older study from 1988 [42]. Most
authors today would probably agree that cys-
tadenoma is virtually always a multicystic neo-
plastic proliferation. The parotid gland is the
most common site (45–50%), and the remain-
ing cases are primarily found in the lip, buccal
mucosa and palate. The common laryngeal
multicystic non-neoplastic lesion, the mucous
retention cyst, is sometimes misinterpreted as a
cystadenoma.
Cystadenomas are slowly growing neoplasms
and, when in the lip, they can clinically be
appreciated as mucoceles. By 2015, only some
30 cases of the papillary variant of cystadenoma
in minor salivary glands had been reported [40],
while since then more than a dozen cases have
been described [43–46].
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Cystadenoma is a well-circumscribed, non-
encapsulated tumour. The columnar or cuboi-
dal epithelium often shows papillary projec-
tions into the lumen, is accompanied by basal
cells, and mucous cells may be frequent. The
mucinous cells are periodic acid Schiff (PAS)-
and alcian blue-positive but negative for S100,
p63, SMA and calponin. The papillary variants
of cystadenomas are positive for p63 and other
basal/myoepithelial cell markers. The lumina
are often filled with an eosinophilic material
consisting of inflammatory, squamous or foamy
cells. The cysts are separated by a rather thin
fibrous connective tissue that not infrequently
contains seromucous glands. There is no atypia,
no mitotic figures and no invasive growth pat-
tern (Fig. 1e).
They have no tendency to recur but, on
exceedingly rare occasions, cystadenocarci-
noma arisen from a pre-existing cystadenoma
has been reported [47, 48].
Sialadenoma Papilliferum
Papillary configuration is frequently seen in
many salivary neoplasms, e.g., WT, oncocy-
toma, polymorphous low-grade adenocarci-
noma (nowadays, polymorphous
adenocarcinoma, PAC; [49]), papillary cystade-
noma, etc. Ductal papillomas comprise a special
group of adenomas with unique papillary fea-
tures. In the 2017 WHO classification, the three
different histologies have been separated into
two entities, sialadenoma papilliferum and
ductal papilloma (intraductal and inverted
type) [50, 51]. Possibly, cystadenoma will
eventually be included in this group of
tumours, as the spectrum of intraductal papil-
lary proliferations appears heterogenous. A
recent amplicon-based massive parallel
sequencing revealed an identical AKT1
p.Glu17Lys mutation in the three cases anal-
ysed, but no concurring mutations in other
genes of the RAS or P13K pathway [52]. The
three cases analysed by Agaimy and associates
may perhaps not fit perfectly with the sialade-
noma papilliferum spectrum and the AKT1
mutant tumours might represent a different
entity.
Sialadenoma papilliferum (SP) is a non-en-
capsulated proliferation with a distinct and
unusual histology comprising both an exo-
phytic mucosal part and an inverted papillary
intramucosal part of both salivary ducts and
mucosal epithelium. The neoplastic part is the
salivary ductal cells in the submucosa, which
proliferate up into the surface epithelium, and
the latter reacts with adjacent hyperplasia and
papillomatosis (Fig. 1f). It is rare and comprises
0.4–1.2% of all salivary gland tumours.
Approximately 80% of cases occur in the palate
(particularly the hard palate), others in
decreasing order in the buccal mucosa, upper
lip, retromolar pad, and parotid gland, but cases
have also been reported in the bronchus and
nasopharynx [53, 54]. The peak age is in the 6th
decade [55]. SP was first described by Abrams
and Finck in 1969 [56] and presents clinically as
a painless exophytic papillary mass, often mis-
interpreted clinically as squamous cell papil-
loma, warty dyskeratoma or verrucous
carcinoma [57]. A literature review in 2007 by
Mahajan et al. [58] found a total of only 47
reported cases, a number that has increased
substantially following the 7 new cases reported
by 2018 [55].
Histologically, there is a biphasic growth
pattern of salivary duct epithelium into the
squamous keratotic epithelium. The exophytic
squamous proliferation is supported by
fibrovascular cores extending up above the
adjacent mucosa, and transition from the
squamous epithelium to the ductal epithelium
can be seen. The proliferating salivary duct
epithelium consists of columnar and cuboidal
cells frequently forming cysts that are CK7-
positive which much of the adjacent papillary
squamous epithelium is not, and the latter
therefore likely represents a reactive squamous
proliferation to the underlying neoplastic sali-
vary ductal proliferation. The cells of the ductal
epithelium tend to have rather large but uni-
form nuclei. These ductal cells are thus strongly
positive to CK7 but also to S-100 (Fig. 1g, h).
Occasionally, mucocytes can be seen in both
the salivary and the squamous epithelium. The
excretory ducts are thus the most likely site of
origin.
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Although recurrences are exceedingly rare, if
they occur at all, a few cases of possible malig-
nant transformation have been reported. In the
case report of a mucoepidermoid carcinoma
arising in a background of SP reported by Liu
and associates. it is not entirely convincing that
the SP had transformed into a mucoepidermoid
carcinoma. It seems more likely that the SP was
a bystander, but the possibility of a high-grade
transformation of the SP cannot be totally
excluded [59]. The second case described was
not an invasive carcinoma but a carcinoma
in situ of the exophytic squamous component
[60]. The third case is possibly the most plausi-
ble one. Shimoda and associates described
malignant transformation in a SP that may well
have been a case of high-grade transformation,
a genetic event not very well known at that time
[61]. In the English world literature, we have
thus only found one or two cases where malig-
nant transformation of the SP may have occur-
red, and therefore we conclude that this tumour
entity virtually has no malignant potential.
Ductal Papilloma: Intraductal Type
The intraductal papilloma (IDP) is a unicystic,
circumscribed or encapsulated lesion consisting
of a dilated salivary duct with papillary projec-
tions into the duct lumen. The majority of the
approximately 30–40 cases of IDPs reported so
far have been located in minor salivary glands;
only 7 cases were reported in the parotid gland,
including a few from the accessory parotid
gland. The aetiology is unknown but a possible
association with masticatory trauma has been
proposed. They are thus most frequently loca-
ted in the lower lip, floor of mouth, palate and
tongue. The cells of the papillary ingrowth are
of the same columnar/cuboidal cells that line
the dilated duct, but there are also sometimes
interspersed goblet-like cells. IDP has a delicate
papillary network of cell-lined vascular fronds
and the papillae partly fill the cystic cavity.
Cytologic atypia and mitoses are virtually
absent [62] (Fig. 2a, b). Papillary cystadenoma,
on the other hand, is a multicystic lesion that
has a variety of epithelial cell types, not only
ductal cells (see ‘‘Cystadenoma’’) [48, 63].
In contrast to its counterpart in the breast
[64], salivary IDP has no tendency to recur and
malignant transformations are virtually
unheard of, apart from a papillary adenocarci-
noma possibly arising from one parotid intra-
ductal papilloma [65].
Ductal Papilloma: Inverted Type
Inverted ductal papilloma is more common
than intraductal type ductal papilloma, and is a
well-known tumour entity arising in many sites
other than salivary glands, e.g., nasal cavity,
paranasal sinuses and urinary bladder. The first
report in the salivary glands was published in
1981 by Batsakis et al., describing an epider-
moid papillary adenoma [66], and the following
year, the tumour was termed inverted ductal
papilloma by White and associates [67], a ter-
minology later embraced by Batsakis as well as
by the 2005 and 2017 WHO classifications
[1, 62, 68]. The study by Brannon and associates
in 2001 revealed 33 reported cases up to that
date [69], a number that today has increased to
well over 50 cases [70]. Virtually all reported
tumours have been located in minor salivary
glands [62], and, on exceedingly rare occasions,
possibly in the major salivary glands [50].
Inverted ductal papilloma is a circumscribed,
well-demarcated but unencapsulated, endo-
phytic papillary proliferation. It arises at the
junction of a salivary gland and the oral mucosa
and the papilloma are frequently continuous
with the overlying mucosal epithelium. The
lesions are often nodular but may also be cystic.
The proliferating epithelial cells have the
appearance of epidermoid and basal cells form-
ing broad papillary projections. There may be
some columnar cells as well as mucous cells and
microcysts. The cells are cytologically bland and
there are few mitotic figures (Fig. 2c). The
endophytic, intraductal component of some
oral condyloma acuminatum histologically has
the appearance of inverted ductal papilloma.
The surface keratinisation and the presence of
koilocytes typical of condyloma acuminatum
are, however, not seen in the intraductal com-
ponent [71]. Some reports have indicated the
presence of HPV 6/11 in inverted ductal
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Fig. 2 a An encapsulated intraductal papilloma in a minor
salivary gland. b Higher magniﬁcation illustrating the
delicate papillary network of cell-lined vascular fronds with
the occasional goblet cell; atypia and mitoses are absent (a,
b by courtesy of Dr Guy Betts, Manchester University
NHS Foundation Trust, UK). c Non-encapsulated
inverted papilloma with an endophytic growth pattern.
The cells have an epidermoid and basal cell appearance and
the tumour frequently contain smaller cysts. Inset Another
example of inverted papilloma. d Canalicular adenoma of
the upper lip with strands of single layered cells of one cell
type and with the hallmark of a very paucicellular and
vascular stroma; morules, i.e., squamous balls, may be
present, either free in the lumen or attached (arrow). Inset
Positive S100 staining, an enigmatic characteristic of
canalicular adenoma. e Basal cell adenoma, primarily
trabecular type, with anastomosing strands and cords of
ductal and basaloid cells. Palisading of nuclei in the outer
cells of the cords. f CK7 stain highlights the two cellular
components of BCA (in contrast to only one in canalicular
adenoma) with positive inner ductal cells and outer CK7
negative myoepithelial/basal cells
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papilloma as well as in inverted ductal papil-
loma associated with condyloma acuminatum
[72, 73]. In contrast, a study from 2013 revealed
no presence of HPV viral DNA in an inverted
ductal papilloma of the lip, but the patient had
a previous history of trauma [74].
The histological features are thus very similar
to those of sinonasal inverted papilloma but, in
contrast to the sinonasal papilloma, recurrence
and/or malignant transformation is not known
to occur.
Canalicular Adenoma
Historically canalicular adenoma was consid-
ered a variant of BCA which was recognised as a
separate entity for the first time in the 1991
WHO classification [4]. This is a peculiar and
histologically a very readily recognisable benign
salivary gland tumour. The vast majority,
60–80%, if not more, occur in the upper lip, the
rest primarily in the buccal mucosa and in the
hard palate, and at other sites, but virtually
never in the major salivary glands [75]. CA
occurs almost exclusively in patients over
50 years of age, is commonly multifocal, well
circumscribed and rarely larger than 2 cm. In
some studies from Western countries, they
represent 7–12% of all benign salivary tumours,
making it the 3rd or 4th most common benign
epithelial salivary tumour [7–9, 76, 77]. In sharp
contrast, in a large study from China comprised
of 737 intraoral minor salivary gland tumours,
not a single case of canalicular adenoma was
reported [10]. The tumour is composed of
columnar and cuboidal cells with eosinophilic
cytoplasm forming bilayered strands, thus con-
sisting of only one cell type, diagnostically
S-100 positive (Fig. 2d). These anastomosing
strands of cells are separated by a loose, pauci-
cellular, highly vascular stroma. This stroma is
characteristically alcian blue- and PAS-positive
(2.5) and CD15-positive.
There are also morules present, i.e., squa-
mous balls, that may lie free in the lumen or be
attached (Fig. 2d). Microliths and tyrosine
crystals may be present. The tumour cells are
positive for S-100 and cytokeratins but negative
for CEA and display a variable reactivity for
EMA. The total lack of duct-surrounding cells,
cells that usually are immunopositive for p63,
calponin, SMA, etc., readily discriminates
canalicular adenoma from, e.g., BCA (the latter
always consists of two cell types with a different
immunophenotype, e.g., CK and p63) or
myoepithelioma of a trabecular type. CAs are in
the vast majority of cases readily recognised on
H&E-stained slides and immunohistochemistry
or special stains are generally not needed, par-
ticularly not when located in the lip. The main
differential diagnosis that could possibly be
considered are PAC, adenoid cystic carcinoma
and BCA. From the large series (67 cases)
reported by Thompson and associates, it
appears evident that it is almost impossible to
distinguish between recurrence or persistence of
multifocality (9 patients had multifocal
tumours, 5 of whom had additional tumours
removed up to decades later). No malignant
transformation was observed [75]. A very rare
case of a total of nine separate nodules in the
upper lip was reported, where one nodule was a
polymorphous low-grade adenocarcinoma
PLGA (recently PAC) synchronous with eight
canalicular adenomas [78]. In a review of 430
cases of CA, recurrence was reported in 3% of
cases [77]. Hence, CA can be considered a
tumour that very rarely recurs, with malignant
transformations yet to be reported.
Basal Cell Adenoma
BCA consists of basaloid cells, with occasional
inner ductal epithelial cells, arranged in four
different cellular growth patterns, described as
solid, trabecular, tubular (tubulo-trabecular)
and membranous. BCA accounts for 1.8–5% of
all salivary gland tumours. It is predominantly a
tumour of major salivary glands with approxi-
mately 75–80% of cases found in the parotid
glands and at least 5% in the submandibular
glands. It tends to occur in elderly patients with
a peak in the seventh decade and with a slight
female predilection, and hence in a rather older
age group than PA [79]. The upper lip is the
most common minor salivary gland origin. In a
study of 6982 minor salivary gland tumours in a
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Chinese population, BCA was extremely rare
[11], but less so in a Western population [80].
At least four growth patterns are recognised
and often combinations thereof may be seen in
the same tumour. The solid type of BCA some-
times resembles a nodular or solid subtype of
basal cell carcinoma of the skin. There are solid
nests of crowded basaloid tumour cells sur-
rounded by a palisading outer layer of columnar
or cuboidal cells. Squamous metaplasia can
occasionally be seen in BCA, hence another
feature in common with skin basal cell carci-
noma. The trabecular type of BCA has basaloid
cells arranged in strands and cords of varying
thickness, although often rather thin and nar-
row. These cords are separated by a fibrous
sometimes cellular stroma. In some areas, the
stroma may be vascular and with thin cords and
the features may mimic a canalicular adenoma.
The tubular type of BCA has strands of basaloid
cells with numerous small duct lumina lined by
cuboidal, often eosinophilic, cells. The lumina
often contain a PAS-positive material. Some
tubular BCAs can be oncocytic. Most often,
BCAs are not purely trabecular or tubular but
contain variable proportions of both elements
and are referred to as tubulo-trabecular BCA.
The inner ductal cells typically stain for CK7 but
the outer myoepithelial cells are positive for
more typical myoepithelial marker such as SMA.
p63 and high-molecular weight cytokeratins
[81, 82] (Fig. 2e, f). The trabecular and tubular
types are more common than the solid and
membranous types, but often the different pat-
terns are coexistent. Usually, one growth pat-
tern predominates and all four types of BCA can
be cystic, and all BCAs are well circumscribed or
encapsulated. Adenoid cystic carcinoma, PAC
and even canalicular adenoma can occasionally
constitute a differential diagnosis. The identifi-
cation of a capsule, no invasive growth pattern,
no or very little atypia present, and a low pro-
liferation index as measured by Ki-67, will
always strongly favour a BCA.
The membranous type of BCA (dermal
anlage type, dermal analogue tumour) was first
reported by Drut in 1974 when describing a
parotid tumour as a ‘‘cutaneous type of cylin-
droma’’ and was later termed ‘‘dermal analogue
tumour’’ by Batsakis and Brannon in 1981, but
in the 2nd WHO classification it is referred to as
membranous type BCA [4, 83, 84]. Membranous
BCA is characterised by multiple nests or islands
of basaloid epithelial cells having palisading of
peripheral cells and a excessive hyaline basal
membrane; hence, there are thick bands of
hyaline material surrounding the epithelial
islands. Both sebaceous and epidermoid differ-
entiation can be seen in the cell islands. Mem-
branous BCAs are multinodular often
multicentric and rarely encapsulated, and
therefore an infiltrative growth pattern is
imparted to this type of BCA. The membranous
BCA resembles the dermal cylindroma and not
infrequently coexists with tumours of the skin,
e.g., eccrine cylindroma or trichoepithelioma of
the scalp (turban tumour) as a part of Brooke–-
Spiegler syndrome. Immunohistochemically, all
BCAs will exhibit ductal and some degree of
myoepithelial differentiation and are positive
for keratin markers such as CK7 and others, but
also, in contrast to canalicular adenoma, vari-
ably positive for myoepithelial markers (SMA,
vimentin, p63, S-100, etc.). It is worth recalling
that both basal cells and myoepithelial cells
stain positive for p63 [6, 85, 86].
The literature gives the histological classifi-
cation for the four types described above no
clinical value apart from separating membra-
nous BCA from the other types. The membra-
nous type of BCA may have a recurrence rate of
as much as 25%, while the other types can be
regarded as non-recurrent tumours [87, 88]. On
rare occasions, malignancy may develop from a
BCA (any subtype) and usually as a basal cell
adenocarcinoma or adenoid cystic carcinoma,
but salivary duct carcinoma and intracapsular
adenocarcinoma NOS and intracapsular
myoepithelial carcinoma have also been repor-
ted. In one series, malignant transformation
occurred in as much as 4.3% [89, 90].
Warthin Tumour (WT)
WT is a benign well-encapsulated parotid
tumour usually occurring in the caudal pole and
is the second most common benign salivary
gland tumour. In a series of 239 benign parotid
tumours, 55.2% were PAs while WTs
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constituted 36.4% [13, 91]. It consists of an
oncocytic epithelial cell component arranged in
double layers which develop cysts and papillary
projections. There is characteristically a stroma
component consisting of a variable amount of
lymphoid tissue. WT was first reported in 1895
[92] and was recognised in 1910 as separate
diagnostic entity called papillary ‘cystadenoma
in lymphatic glands’ [92, 93]. In 1929, Warthin
described the reported cases of this tumour up
to that date and thus it later became known as
the Warthin tumour [94]. WTs rather frequently
arise in intra- and periparotid lymph nodes,
and, in two series of 333 and 176 cases of WTs, 9
(2.7%) and 14 (8%) were located in parotid
lymph nodes, respectively [95–97]. WT is almost
exclusively found in the parotid but a few cases
in the submandibular gland, palate, buccal
mucosa, lips, larynx and nasopharynx have
been reported [90, 98].
WT is the most common synchronous mul-
tiple salivary gland tumour followed by PA
[13, 99–101]. Multiple salivary gland tumours
should be distinguished from tumours with
biphasic differentiation and from so-called
hybrid tumours. Synchronous benign and
malignant salivary gland tumours are very rare
but WT and mucoepidermoid carcinoma are the
most common combination [102]. In a study of
341 patients with parotid tumours, syn-
chronous multiple tumours were found in 14
cases, 9 of which were WTs [103]. In another
series of 78 WTs, multiple tumours were repor-
ted in as many as 20% of cases, and a third of
these cases were also bilateral [104]. Bilateral
WTs were found in 10% of cases in a study of 73
patients [105]. The high tendency for multiple
tumours has to be considered when a second
tumour arises, i.e., is that a true recurrence or is
it a tumour left behind at the first surgical
exploration? In a cross-sectional study of 628
parotid tumours, there were 150 cases of WT
(24%), and in approximately 10% of cases the
tumours were multicentric. In cases of solitary
WT, the recurrence rate was 0% and while it was
10% in the multicentric tumour group [106].
Multifocality and bilaterality are especially
important in heavy smokers and every effort
should be made to promote smoking cessation
in these patients.
Malignant transformation of WTs is rare.
Carcinoma in WT does not necessarily imply
malignant transformation of the epithelial
oncocytic component, as synchronous benign
and malignant salivary gland tumours do exist,
albeit rarely, and WT and mucoepidermoid
carcinoma is the most common observed com-
bination. In 1997, Seifert described five malig-
nancies which had arisen in WTs, and the
histological criteria for malignant transforma-
tion in a WT should include a continuous
transition zone from the benign double-layered
oncocytic epithelium into an invasive epithelial
malignancy [107]. Based on Seifert’s report and
subsequent published cases, the literature con-
tains only approximately 50 carcinoma cases,
squamous cell carcinoma being the most com-
mon, but mucoepidermoid carcinoma, onco-
cytic carcinoma, adenocarcinoma, salivary duct
carcinoma, acinic cell carcinoma and undiffer-
entiated carcinoma have also been reported
[108–113]. In some of the reported cases, WTs
developing into mucoepidermoid carcinomas
could represent WTs with extensive mucocyte
metaplasia or pure Warthin-like variants of
mucoepidermoid carcinoma and thus the fig-
ure given above of 50 cases is likely too high.
WTs, both in the parotid gland or neigh-
bouring lymph nodes, may occasionally be
associated with different lymphoproliferative
disorders and some 20 cases have been reported,
possibly several of which have been collision
tumours. Non-Hodgkin lymphomas are most
common [114–116], but a few cases of Hodg-
kin’s lymphoma have also been reported
[117, 118]. A few cases of nodal peripheral T cell
lymphoma [119] and MALT-type lymphoma
[120] associated with WT have been described.
Myoepithelioma (MYO)
MYO is defined as a tumour composed of
myoepithelial cells that exhibit spindle,
epithelioid, plasmacytoid or clear cytoplasmic
features. The tumour is made up of myoep-
ithelial cells alone or with the addition of very
small numbers of ductal structures. The cells are
arranged in different patterns and grow in a
mucoid, collagenous or vascular stroma.
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Myoepitheliomas were previously thought to
lack the myxoid or chondroid stroma typical of
PA, but such stromal changes are nowadays
recognised to be present. MYO may hence be
histologically very similar to PA, and the scar-
city, or total lack, of duct-like structures may be
the only distinguishing feature. They are
encapsulated or at least well-circumscribed
tumours and the majority arise in the parotid
gland. The proportion of myoepitheliomas
located in the parotid gland range from 40 to
90% in different reported studies series and of
intraoral minor salivary glands, the palatal
glands are most commonly affected. MYO may
occasionally arise in the submandibular gland
but only a dozen of cases have been reported in
the English literature. Myoepithelioma are
much less prone to recur than PA and recur-
rence appears to be strongly correlated with
incomplete surgery [121].
Malignant transformation to myoepithelial
carcinoma may occur but is exceedingly rare
[122, 123]. The few reported cases of myoep-
ithelial carcinoma appear to have arisen in two
different settings; either de novo or in a recur-
rent PA, and thus only very rarely from a pre-
existing MYO [124–127].
Pleomorphic Adenoma (PA)
Since its first description by Billroth in 1859, the
terminology for this entity has veered between
‘‘mixed tumour’’, complex adenoma and PA. In
spite of that, it has a prominent mesenchymal-
appearing ‘‘stromal’’ component, and is not a
truly mixed neoplasm, i.e., it is derived from
more than one germ layer. PA is of purely
epithelial origin characterised by a dual cell
population of neoplastic cells and ductal and
myoepithelial (possibly also basal) cells where
the ‘‘mesenchymal’’ part of a PA is the result of a
metaplastic process of the neoplastic myoep-
ithelial cells. PAs show a vast number of differ-
ent microscopic patterns depending on the
arrangement of the epithelial cells and how
much and what type of stroma is present. The
morphology of PA is well known to any
pathologist, and it is beyond the scope of this
article to describe and illustrate all the different
oncocytic, osseous, sebaceous and lipomatous
metaplasia, as well as pigmented variants of PA,
and infarcted PA. The concepts of PA with
atypical features, metastasizing PA, subclassifi-
cation of CXPA into non-invasive (intracapsu-
lar, in situ), and minimally invasive (B 1.5 mm)
and widely invasive CXPA, are of interest as the
tumours belonging to the first two groups
(in situ and minimal invasive) have an excellent
prognosis and, apparently need no adjuvant
treatment to radical surgery [128].
In the present study, our interest in PA is
primarily focused on the fact that PA is by far
the most common salivary gland neoplasm, and
can also, in small biopsy specimens, mimic
other salivary gland tumours and even be con-
fused with malignant tumours. Other very
important features for this study are the ten-
dency of PA to recur, and not at least that overt
malignancy develops in at least 5–15% of cases
which makes CXPA the 4th or 5th most com-
mon malignant salivary gland tumour [129]. In
Denmark, the rate of malignant transformation
has been reported in 2% of cases [130]. PAs are
generally slow-growing tumours often present
for years before the patients seek medical
advice. Most are located in the tail of the par-
otid gland and only 10% are present in the deep
portion of the gland beneath the facial nerve
and may then present as a parapharyngeal mass.
The treatment of PA is complete surgical
excision which will constitute cure in a vast
percentage of cases. The extension of the sur-
gery in parotid gland tumours is controversial.
Different surgical options co-exist nowadays,
and the discussion between the more limited
resections (extracapsular dissection) in front of
more classical options (partial, superficial or
total parotidectomy) is still very alive. Different
schools favour one option or another depend-
ing on their experience, their skill and their
tradition, but probably the surgery should be
adapted to the size and the situation of the
tumour [131, 132]. For PAs in minor salivary
glands, or if not situated in the superficial par-
otid lobe, complete surgical excision is not
always readily performed. PA is rarely multifocal
and, with current management of parotid PA,
the recurrence rate is estimated to be 2.9%
[130].
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As pointed out in recent reviews, the most
important cause of recurrent PA is enucleation
with rupture of the tumour capsule and
incomplete tumour excision at operation.
Incomplete pseudocapsule, extracapsular
extension, pseudopodia of PA tissue, and satel-
lite PA beyond the pseudocapsule are also likely
linked to recurrent PA. Tumour spillage is
clearly involved in recurrences. In a study of the
outcome of parotid surgery in 182 cases, tumour
disruption and spillage had an independent
effect on recurrence: 26.9% recurrences in dis-
ruption and 80% in spillage [133, 134].
Malignant transformation (CXPA) usually
occurs in recurrent PAs that have been present
for long periods of time, and in some series as
long as 23 years, while in other series 45% of
tumours had, however, been present for less
than 3 years [135, 136]. CXPA tends to present
late in life, often in the 6th and 7th decades,
which is a decade later than PA. CXPA most
commonly arises in the parotid gland and only
rarely in the submandibular gland
[129, 137–139]. Virtually any salivary type car-
cinoma may develop, possibly with the excep-
tion of acinic cell carcinoma, and usually only
one histological type is encountered. In an
extensive literature review by Gnepp, he found
42 cases of carcinosarcoma and, in at least 11 of
these cases, there was a previous history of PA
[129]. Inadequate surgical procedures leading to
multiple recurrences appear in most cases to be
a prerequisite for malignant transformation but
also for metastatic disease [140–143]. However,
83.6% of CXPA are de novo in Denmark, i.e. no
previous operation for CXPA [130].
DISCUSSION
The data collected from the literature indicate
rather clear differences in clinical behaviour
between the different benign epithelial salivary
gland tumours—even when given adequate
initial surgical treatment. PA is overwhelmingly
the most common of all salivary neoplasms
and, due to its high tendency for recurrence and
malignant transformation, and with its broad
histological spectrum, is the most important
benign salivary tumour to diagnose correctly. In
many decent-sized biopsy specimens, and core
biopsies, even experienced pathologists can
confuse PA with several of the other benign,
and malignant, salivary neoplasms, e.g.,
epithelial–myoepithelial carcinomas, polymor-
phous low-grade adenocarcinoma (although PA
does not have the typical nuclei of cribriform
type of PAC) and some adenoid cystic carcino-
mas. The myoepithelial/basal outer cells of the
duct-structures in PAs and other tumours may
be spindle-shaped, epithelial or clear cell in
appearance. In cases with a mucoid/myxoid
stroma with typical stellate and epithelioid
myoepithelial cells, the ductal-like cells are p63
negative and the myoepithelial cells p63 posi-
tive. Similarly, in this myxoid/mucoid variant,
both cellular elements are positive for vimentin,
S-100, and pancytokeratin, and many but not
all of the myoepithelial cells are negative. Other
keratin markers like pancytokeratin, CK 5/6,
CK14 and CK8/18 similarly give a strong stain-
ing of the ductal cells but tend to stain the
myoepithelial cells more weakly. The most
reliable markers for both types of cellular ele-
ments in this type of PA are, hence, p63, CK5/6,
CK8/18, vimentin and S-100. It may be
emphasised that the p63 and p73 genes are
members of the p53 family and in contrast to
p53 play important roles in stem cell identity
and cellular differentiation. Both are expressed
in basal and myoepithelial cells, but it appears
that p63 is a more specific marker of myoep-
ithelial differentiation than p73. All isoforms of
p63 are said to be expressed in normal salivary
tissue, whereas PAs (as well as myoepitheliomas
and BCAs) dominantly express the transactiva-
tion-incompetent truncated isoforms. Negative
PLAG1 immunostaining will rather strongly
support that the salivary tumour is not a PA,
and positive PLAG1 staining does not neces-
sarily indicate a PA, as it is present, for example,
in some CXPA.
In some PAs, there are areas where the pro-
liferating cells have a reticular (canalicular-like)
growth pattern and may mimic a canalicular
adenoma. Tumours with numerous myoep-
ithelial cells of the plasmacytoid type are more
commonly found in minor salivary gland PAs
(and MYOs). The plasmacytoid tumours tend to
be positive for vimentin, cytokeratin, S-100 and
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GFAP while negative for SMA and MSA. This is
in contrast to tumours with predominantly
spindle-shaped myoepithelial cells which tend
to be positive for SMA and MSA, in addition to
sharing the positivity for the other four mark-
ers. The staining patterns for SMA and MSA are
in keeping with the relative absence of myoge-
nous differentiation in the plasmacytoid cells.
In biopsies from minor salivary gland tumours,
caution is warranted not to confuse a PA with
polymorphous low-grade adenocarcinoma and
adenoid cystic carcinoma. Recently, the E710D
hotspot mutation in the PRKD1 gene has been
shown to have a 100% specificity in separating
PAC from PA and adenoid cystic carcinoma on
fine needle aspiration (FNA) [144].
Vascular tumour invasion, particularly cap-
sular vascular invasion, is a rare and well-
known, but also a much debated, feature of PA.
The biological significance is not known but the
general concept is that this does not indicate
malignancy. It may of course be related to the
enigma of metastasizing PA. In a study by Ska-
lova and associates, 22 cases of PA were
demonstrated to have intravascular tumour
deposits. In 7 of these patients, a FNA had pre-
viously been performed which possibly could be
related to the intravascular tumour deposits.
Tumour cells were found in both thin-walled
and muscular thick-walled vessels [145]. PAs
show a myriad of different histological appear-
ances while myoepitheliomas are morphologi-
cally much more monotonous. MYOs are
generally considerably more cellular, show less
metaplastic phenomena, have very few ductal
structures and small or no amounts of muci-
nous/myxoid/chondroid stroma. Some authors
require a total absence of ductal elements for
the classification of MYO. The immunopheno-
type will depend on which one(s) of the four
main histological types of neoplastic myoep-
ithelial cells (briefly described above) the
tumour consists of. The significantly lower rate
of recurrence and virtually no malignant
potential merit their distinction as a separate
entity and separation from PA. Caution also has
to be taken in cases of cystic PA with squamous
metaplasia so as not to be confused with low-
grade mucoepidermoid carcinoma.
BCAs, other than perhaps the membranous
type, may constitute a differential diagnosis. It
is worth remembering that at least 80% of BCAs
are located in major salivary glands and are thus
relatively rare in minor salivary glands. They all
have two cellular components, clearly expressed
by immunohistochemistry, and they do not
express PLAG1. The membranous type’s rela-
tively high tendency for recurrence, and the
potential for malignant transformation in all
four types, are factors that demand their
recognition and separation from other
adenomas.
WT was for a long period of time regarded as
not having any malignant potential, and to that
extent some 20–30 years ago elderly patients
with no symptoms, and no major cosmetic
concerns, were offered the choice of surgery or
leaving the lump as it was. Today, a sufficient
number of cases of malignancy arising in WTs
have been reported, and, combined with our
knowledge of its great tendency for syn-
chronous tumours, many cases likely do war-
rant a surgical intervention.
Intraductal papilloma, inverted papilloma,
lymphadenoma, sebaceous adenoma, cystade-
noma, sialadenoma papilliferum, oncocytoma,
canalicular adenoma, and myoepithelioma are
rare entities that can be diagnosed correctly
with sufficient experience. However, their
diagnosis currently carries few clinical implica-
tions with the exception that some of them
have a remote tendency to recur, and may
occasionally be confused with a malignant
neoplasm. It is again emphasised that sialade-
noma papilliferum is a non-encapsulated pro-
liferation while intraductal and inverted
intraductal papilloma are circumscribed.
Sialadenoma papilliferum and intraductal
papilloma consist primarily of ductal columnar
and cuboidal cells while an inverted papilloma
consists primarily of epidermoid-like (ductal)
cells. Mucoepidermoid carcinoma may theoret-
ically constitute a histological differential diag-
nosis in cases of sialadenoma papilliferum and
inverted ductal papilloma, while, as in cases of
intraductal papilloma being an unicystic
tumour, cystadenoma should not be a realistic
differential diagnosis.
1966 Adv Ther (2019) 36:1950–1974
Over the years, recurrent benign salivary
tumours have mainly been blamed on inade-
quate surgical procedures or spillage from FNAs.
Recent epigenetic studies on tumours and
tumour-adjacent tissue in other organs
[146–148], as well as ongoing studies on salivary
gland tissue (unpublished data), may possibly
reveal that other factors play a role and that the
surgical technique is not always to be blamed
for recurrences. The remaining tumour host
organ tissue itself may have undergone genetic
and/or epigenetic changes, although micro-
scopically it looks normal. These changes could
be responsible for stimulating the proliferation
of a new tumour rather than the second tumour
being a recurrence due to tumour tissue left
behind after the first operation/or spillage.
CONCLUSION
Based on our findings of the histology and
clinical behaviour of the different tumour
entities, we emphasise the need for correct his-
tological recognition of all benign salivary
tumours, but particularly PA with all its histo-
logical variants, the different variants of BCA
and WT. It may seem superfluous in the latter
case, but a careful examination of any epithelial
dysplasia or suggestions of lymphoproliferative
disorder is necessary. The diagnosis of the other
types of benign epithelial tumours will give
guidance for the risk for recurrence, and careful
histopathological diagnosis to avoid confusion
with a malignant salivary gland tumour is, of
course, a necessity (see Supplementary
material).
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